Clinical trial
The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and…
NCT00065325 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00065325 |
|---|---|
| Title | The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer |
| Official title | A Randomized, Double Blind, Multicenter Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX™) vs. Exemestane (AROMASIN™) in Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer With Disease Progression After Prior Non-Steroidal Aromatase Inhibitor (AI)… |
| Acronym | EFECT |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Locally Advanced Breast Cancer, Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | Fulvestrant, Exemestane |
| Enrollment | 694 |
| Start date | Aug 1, 2003 |
| Primary completion | Jun 1, 2006 |
| Completion | Sep 1, 2014 |
| First posted | Jul 23, 2003 |
| Last update posted | Feb 24, 2015 |
| Countries | Argentina, Belgium, Brazil, Canada, Denmark, France, Germany, Hungary, Israel, Russia, South Africa, Spain and 3 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: